| Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance E Raschi, M Gatti, F Gelsomino, A Ardizzoni, E Poluzzi, F De Ponti Targeted Oncology 15, 449-466, 2020 | 103 | 2020 |
| Assessment of a PK/PD target of continuous infusion beta-lactams useful for preventing microbiological failure and/or resistance development in critically ill patients affected … M Gatti, PG Cojutti, R Pascale, T Tonetti, C Laici, A Dell’Olio, A Siniscalchi, ... Antibiotics 10 (11), 1311, 2021 | 51 | 2021 |
| Expert clinical pharmacological advice may make an antimicrobial TDM program for emerging candidates more clinically useful in tailoring therapy of critically ill patients M Gatti, PG Cojutti, M Bartoletti, T Tonetti, A Bianchini, S Ramirez, ... Critical Care 26 (1), 178, 2022 | 50 | 2022 |
| Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID‐19 M Gatti, M Fusaroli, P Caraceni, E Poluzzi, F De Ponti, E Raschi British journal of clinical pharmacology 87 (3), 1533-1540, 2021 | 49 | 2021 |
| A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug … M Gatti, M Bartoletti, PG Cojutti, P Gaibani, M Conti, M Giannella, P Viale, ... Journal of Global Antimicrobial Resistance 27, 294-298, 2021 | 45* | 2021 |
| Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs M Gatti, M Andreoni, F Pea, P Viale Drug Design, Development and Therapy, 3349-3378, 2021 | 42 | 2021 |
| Advances in the therapy of bacterial bloodstream infections M Giannella, M Bartoletti, M Gatti, P Viale Clinical Microbiology and Infection 26 (2), 158-167, 2020 | 40 | 2020 |
| Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections M Meschiari, S Volpi, M Faltoni, G Dolci, G Orlando, E Franceschini, ... JAC-Antimicrobial Resistance 3 (4), dlab188, 2021 | 39 | 2021 |
| Clinical outcome in solid organ transplant recipients affected by COVID-19 compared to general population: a systematic review and meta-analysis M Gatti, M Rinaldi, L Bussini, C Bonazzetti, R Pascale, Z Pasquini, F Faní, ... Clinical Microbiology and Infection 28 (8), 1057-1065, 2022 | 38 | 2022 |
| Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues M Gatti, E Turrini, E Raschi, P Sestili, C Fimognari Pharmaceuticals 14 (8), 738, 2021 | 38 | 2021 |
| Serotonin syndrome by drug interactions with linezolid: clues from pharmacovigilance-pharmacokinetic/pharmacodynamic analysis M Gatti, E Raschi, F De Ponti European journal of clinical pharmacology 77, 233-239, 2021 | 38 | 2021 |
| Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors M Gatti, F Pea Expert Review of Clinical Pharmacology 14 (5), 583-599, 2021 | 33 | 2021 |
| Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system M Gatti, IC Antonazzo, I Diemberger, F De Ponti, E Raschi European journal of preventive cardiology 28 (9), 983-989, 2021 | 32 | 2021 |
| Antimicrobial dose reduction in continuous renal replacement therapy: myth or real need? A practical approach for guiding dose optimization of novel antibiotics M Gatti, F Pea Clinical Pharmacokinetics 60 (10), 1271-1289, 2021 | 31 | 2021 |
| Assessing the association between fluoroquinolones and emerging adverse drug reactions raised by regulatory agencies: an umbrella review M Gatti, M Bianchin, E Raschi, F De Ponti European Journal of Internal Medicine 75, 60-70, 2020 | 31 | 2020 |
| Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections M Gatti, F Pea Current Opinion in Infectious Diseases 34 (6), 737-747, 2021 | 30 | 2021 |
| Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities M Gatti, F De Ponti Pharmaceutics 13 (3), 302, 2021 | 30 | 2021 |
| Liver injury with ulipristal acetate: exploring the underlying pharmacological basis M Gatti, E Poluzzi, F De Ponti, E Raschi Drug Safety 43, 1277-1285, 2020 | 28 | 2020 |
| Assessment of adverse reactions to α-lipoic acid containing dietary supplements through spontaneous reporting systems M Gatti, I Ippoliti, E Poluzzi, IC Antonazzo, PA Moro, U Moretti, ... Clinical Nutrition 40 (3), 1176-1185, 2021 | 24 | 2021 |
| The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia M Gatti, E Raschi, E Poluzzi, C Martignani, S Salvagni, A Ardizzoni, ... Current Heart Failure Reports 17, 365-383, 2020 | 24 | 2020 |
